Gen Digital Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Gen Digital Inc. Common Stock trades at $23.76 (market cap $14.24B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Gen Digital Inc. Common Stock is the larger of the two by market cap, and Gen Digital Inc. Common Stock pays a 2.1% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gen Digital Inc. Common Stock for 6 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| GEN | PCVX | |
|---|---|---|
Market Cap | $14.24B | $10.51B |
Volume | 6,202,699 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $31.41 | $73.82 |
52-Week Low | $17.89 | $40.32 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $21.89B | $9.14B |
Dividend Yield | 2.1% | — |
Signals from Pluang's Aura AI — not financial advice
GEN Digital Inc. (GEN) trades at $23.81, up 1.97% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 13.92, net income margin of 20.73%, and robust cash flow from operations of $1.22B in 2025. Recent news highlights include a takeover bid for GoDaddy and participation in investor conferences, reflecting strategic moves in the cybersecurity and digital services sector.
The outlook is mixed: analyst consensus targets $25.50 with a balanced buy/hold split, but technical indicators suggest near-term pressure. Key risks include high debt levels and integration challenges from acquisitions. Earnings growth and market expansion into AI services present opportunities, though volatility may persist amid competitive and macroeconomic headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Gen Digital provides cybersecurity, online privacy, identity protection, and financial wellness services. Its consumer brands include Norton, Avast, LifeLock, and MoneyLion.
Read more on GEN →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →